YiChang HEC ChangJiang Pharmaceutical : VOLUNTARY ANNOUNCEMENT ENTACAPONE TABLETS APPROVED TO LAUNCH

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜 昌 東 陽 光 長 江 藥 業 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT

ENTACAPONE TABLETS APPROVED TO LAUNCH

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis.

The board of directors (the ''Board'') of the Company is pleased to announce that Entacapone Tablets (0.2g) (the ''Product'') acquired by the Company from Sunshine Lake Pharma Co., Ltd. (''Sunshine Lake Pharma'') have undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration. Subsequently, the marketing authorization holder of the Product will be changed to the Company or a subsidiary controlled by the Company through supplemental application.

The Product is used as an adjuvant to the standard drugs, namely levodopa/benserazide or levodopa/carbidopa, for Parkinson's disease and end-of-dosewearing-off (symptom fluctuations) whereas it is uncontrollable by the above drugs. Entacapone is a reversible, specific and peripheral catechol-O-methyltransferase (''COMT'') inhibitor which is mainly used with levodopa preparations.

Entacapone belongs to Class B (乙類品種) under the National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (國家基本醫療 保險、工傷保險和生育保險藥品目錄) (2020 edition). According to the data from IQVIA, the sales of Entacapone in China in 2020 was approximately USD11.1750 million, representing an increase of 8.35% as compared to 2019.

- 1 -

The Product is the first generic drug which obtained the approval for launch in China. After obtaining the approval for launch, it will be deemed to have passed the generic drug quality and efficacy consistency evaluation (the ''Consistency Evaluation''). The Product is also the first drug which passed the Consistency Evaluation. The Product is considered as drugs with high clinical value and favourable market prospects and will become one of the Company's products in the field of nervous system disease treatment after its launch. The launch of the Product will further enrich the Group's product portfolio and will also provide patients with a choice of medication with high quality and fair price.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Tang Xinfa

Chairman

Hubei, the PRC

7 April 2021

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.

- 2 -